Covid-19 vaccine Zydus Cadila get DCGI nod for human clinical trials
A potential Covid-19 vaccine indigenously developed by the Ahmedabad-based Zydus Cadila Healthcare Ltd has got the nod
New Delhi: A potential Covid-19 vaccine indigenously developed by the Ahmedabad-based Zydus Cadila Healthcare Ltd has got the nod from the Drugs Controller General of India (DCGI) for human clinical trials.
The approval process was fast-tracked following recommendation by the subject expert committee on Covid-19.
The assent for human trials was given after the company submitted data of clinical trial on animals to the DCGI in which the vaccine candidate was found to be successful with respect to safety, the source said.
The country's 'first' indigenous COVID-19 vaccine candidate Covaxin, developed by Hyderabad-based Bharat Biotech in collaboration with the Indian Council of Medical Research and National Institute of Virology (NIV), had recently got the nod for human clinical trials from the DCGI.